Systemic lupus erythematosus is a chronic inflammatory disease that involves swelling and pain, most commonly on face. The disease affects many parts of the body including skin, joints, kidneys, pleura, pericardium and brain. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. As of now there is no cure for systemic lupus erythematosus, but medical interventions and lifestyle changes can help in improving quality of life. The [b]systemic lupus erythematosus[/b] market can be mild to severe in its form. The cause of systemic lupus erythematosus is unknown, but it is most likely linked to genetic, environmental and hormonal factors. The chance of developing systemic lupus erythematosus is 10 times greater in women as compared to men.

Read report summary here : [b]http://bit.ly/2u0gMYj[/b]

Systemic lupus erythematosus includes symptoms such as oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is diagnosed by examining the symptoms, physical examination, X-rays and lab tests.

Systemic lupus erythematosus treatment involves a combination approach as number of organs are involved. The treatment consists immunosuppressive drugs that inhibit activity of the immune system. The most common approach to treat systemic lupus erythematosus is the use of hydroxychloroquine and corticosteroids including prednisone.

Request sample report here : [b]http://bit.ly/2FYQfPv[/b]

As of April 2017, the systemic lupus erythematosus pipeline comprises of approximately 57 active drug candidates in different stages of development.

Key Players

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.